Citations

Clear

1828 citation(s) found for "Su, Emily".

Comparison of Bacterial Antigen Test and Gram Stain for Detecting Classic Meningitis Bacteria in Cerebrospinal Fluid
Karre, Tess, Vetter, Emily A., Mandrekar, Jayawant N. , Patel, Robin , Patel, Robin

Mayo Clinic

Journal of Clinical Microbiology | February 11, 2010 | Volume: 48 | Issue: 4 | Pages: 1504-1505

10.1128/jcm.00153-10 | PMID 20147643 Get It

Acylcarnitine Analysis by Tandem Mass Spectrometry
Smith, Emily H., Matern, Dietrich

Mayo Clinic

Current Protocols in Human Genetics | January 15, 2010 | Volume: 64 | Issue: 1 | Pages: No page available

10.1002/0471142905.hg1708s64 | PMID 20063265 Get It

AbstractCarnitine plays an essential role in fatty acid metabolism, as well as modulation of intracellular concentrations of free coenzyme A by esterification of acyl residues. Acylcarnitine analysis of various biological fluids is a sensitive method to detect >20 inborn errors of metabolism that result in abnormal accumulation of acylcarnitine species due to several organic acidemias and most fatty acid β‐oxidation disorders. In addition, acylcarnitine analysis may aid in monitoring treatment of known patients affected with these inborn errors of metabolism. This unit describes protocols that can be used to measure acylcarnitine species of various carbon chain lengths in several biological specimen types including plasma, dried blood and bile spots, and urine, by derivatization to butylesters and flow‐injection electrospray ionization tandem mass spectrometry (ESI‐MS/MS). Curr. Protoc. Hum. Genet. 64:17.8.1‐17.8.20. © 2010 by John Wiley & Sons, Inc.
Mesenchymal Stem Cell Carriers Protect Oncolytic Measles Viruses from Antibody Neutralization in an Orthotopic Ovarian Cancer Therapy Model
Mader, Emily K., Maeyama, Yoshihiro, Lin, Yi , Butler, Greg W., Russell, Holly , Russell, Stephen J. , Dietz, Allan B. , Peng, Kah-Whye , Galanis, Evanthia , Dietz, Allan B , Russell, Stephen J , Lin, Yi

Mayo Clinic

Clinical Cancer Research | November 25, 2009 | Volume: 15 | Issue: 23 | Pages: 7246-7255

10.1158/1078-0432.ccr-09-1292 | PMID 19934299 Get It

Abstract Purpose: Preexisting antiviral antibodies in cancer patients can quickly neutralize oncolytic measles virus (MV) and decrease its antitumor potency. In contrast to “naked” viruses, cell-associated viruses are protected from antibody neutralization. Hence, we hypothesized that measles virotherapy of ovarian cancer in measles-immune mice might be superior if MV-infected mesenchymal stem cell (MSC) carriers are used. Experimental Design: Antimeasles antibodies titers in ovarian cancer patients were determined. The protection of MV by MSC from antimeasles antibodies, the in vivo biodistribution profiles, and tumor infiltration capability of MSC were determined. Measles-naïve or immune tumor–bearing mice were treated with naked virus or MSC-associated virus and mice survivals were compared. Results: MSC transferred MV infection to target cells via cell-to-cell heterofusion and induced syncytia formation in the presence of high titers of antimeasles antibody, at levels that completely inactivated naked virus. Athymic mice bearing i.p. human SKOV3ip.1 ovarian tumor xenografts passively immunized with measles-immune human serum were treated with saline, naked MV, or MV-infected MSC. Bioluminescent and fluorescent imaging data indicated that i.p. administered MSC localized to peritoneal tumors, infiltrated into the tumor parenchyma, and transferred virus infection to tumors in measles naïve and passively immunized mice. Survival of the measles-immune mice was significantly enhanced by treatment with MV-infected MSC. In contrast, survivals of passively immunized mice were not prolonged by treatment with naked virus or uninfected MSC. Conclusions: MSC should be used as carriers of MV for intraperitoneal virotherapy in measles-immune ovarian cancer patients. (Clin Cancer Res 2009;15(23):7246–55)
Safety Studies on Intrahepatic or Intratumoral Injection of Oncolytic Vesicular Stomatitis Virus Expressing Interferon-β in Rodents and Nonhuman Primates
Jenks, Nathan, Myers, Rae, Greiner, Suzanne , Thompson, Jill , Mader, Emily K., Greenslade, Andrew, Griesmann, Guy E., Federspiel, Mark J. , Rakela, Jorge , Vile, Richard G. , Barber, Glen N. , Meier, Thomas R., Blanco, Michael C., Carlson, Stephanie K., Russell, Stephen J. , Peng, Kah-Whye , Jenks, Nathan J., Borad, Mitesh J. , Russell, Stephen J

Mayo Clinic

Human Gene Therapy | November 13, 2009 | Volume: 21 | Issue: 4 | Pages: 451-462

10.1089/hum.2009.111 | PMID 19911974 Get It

Functional Restoration of BRCA2 Protein by Secondary BRCA2 Mutations in BRCA2 -Mutated Ovarian Carcinoma
Sakai, Wataru , Swisher, Elizabeth M. , Jacquemont, Céline, Chandramohan, Kurapaty Venkatapoorna, Langdon, Simon P. , Wurz, Kaitlyn, Villegas, Emily, Couch, Fergus J. , Higgins, Jake , Taniguchi, Toshiyasu , Swisher, Elizabeth M

Mayo Clinic

Cancer Research | August 4, 2009 | Volume: 69 | Issue: 16 | Pages: 6381-6386

10.1158/0008-5472.can-09-1178 | PMID 19654294 Get It

Abstract Acquired platinum resistance is a serious problem in the treatment of ovarian carcinomas. However, the mechanism of the drug resistance has not been elucidated. Here, we show functional significance of restoration of BRCA2 protein by secondary BRCA2 mutations in acquired drug resistance of BRCA2-mutated ovarian carcinoma. Three ovarian cancer cell lines (PEO1, PEO4, and PEO6) were derived from a BRCA2 mutation [5193C>G (Y1655X)] carrier with ovarian carcinoma with acquired cisplatin resistance and a secondary BRCA2 mutation [5193C>T (Y1655Y)] that canceled the inherited mutation. PEO1 was BRCA2 deficient and sensitive to cisplatin and a poly(ADP-ribose) polymerase inhibitor, AG14361, whereas PEO4 was resistant. PEO4 and PEO6, derived from ascites at the time of relapse with cisplatin resistance, had the secondary mutation and were BRCA2 proficient. In vitro cisplatin/AG14361 selection of PEO1 led to restoration of BRCA2 due to another secondary BRCA2 mutation. BRCA2 depletion sensitized BRCA2-restored PEO1 clones and PEO4 to cisplatin/AG14361. Thus, restoration of BRCA2 due to secondary BRCA2 mutation is involved in acquired drug resistance of BRCA2-mutated ovarian carcinoma. [Cancer Res 2009;69(16):6381–6]
O2‐06‐04: Intraneuronal Aβ accumulation in Alzheimer's disease
Poduslo, Joseph F., Gilles, Emily J., Ramakrishnan, Muthu, Wengenack, Thomas M., Curran, Geoffry L., Kandimalla, Karunya K.

Mayo Clinic

Alzheimer's & Dementia | June 25, 2009 | Volume: 5 | Issue: 4S_Part_4 | Pages: No page available

10.1016/j.jalz.2009.05.364 Get It

Enhancement of DNA Flexibility in Vitro and in Vivo by HMGB Box A Proteins Carrying Box B Residues
Sebastian, Nadia T. , Bystry, Emily M., Becker, Nicole A. , Maher, L. James

Mayo Clinic

Biochemistry | January 26, 2009 | Volume: 48 | Issue: 10 | Pages: 2125-2134

10.1021/bi802269f | PMID 19236006 Get It

β-Lactam and Fluoroquinolone Combination Antibiotic Therapy for Bacteremia Caused by Gram-Negative Bacilli
Al‐Hasan, Majdi N. , Wilson, John , Lahr, Brian D. , Thomsen, Kristine M., Eckel‐Passow, Jeanette E. , Vetter, Emily A., Tleyjeh, Imad M. , Hanson, Kristine T. , Baddour, Larry M. , Tleyjeh, Imad M , Hanson, Kristine

Mayo Clinic

Antimicrobial Agents and Chemotherapy | January 22, 2009 | Volume: 53 | Issue: 4 | Pages: 1386-1394

10.1128/aac.01231-08 | PMID 19164144 Get It

ABSTRACT The role of combination antibiotic therapy with a beta-lactam and a fluoroquinolone for bacteremia caused by gram-negative bacilli, to our knowledge, has not been previously described. Much of the previous study of combination therapy has included beta-lactams and aminoglycosides. We conducted a large retrospective cohort study to evaluate 28-day all-cause mortality in patients with monomicrobial bacteremia due to aerobic gram-negative bacilli who received either a combination of beta-lactams and fluoroquinolones or beta-lactam monotherapy. We enrolled adult patients admitted to Mayo Clinic hospitals from 1 January 2001 to 31 October 2006 in the study. After stratification of patients by Pitt bacteremia scores, we used Cox regression models to estimate the hazard ratios (HR) for 28-day all-cause mortality after adjusting for the propensity to receive combination therapy. We identified 398 and 304 unique patients with bacteremia caused by gram-negative bacilli who received single and combination antibiotic therapy, respectively. In less severely ill patients with Pitt bacteremia scores of <4, combination therapy was associated with lower 28-day mortality than single therapy (4.2% [9 of 214] versus 8.8% [28 of 319]; adjusted HR, 0.44; 95% confidence interval [CI], 0.20 to 0.98; P = 0.044). In critically ill patients with Pitt bacteremia scores of ≥4, there was no difference in 28-day mortality between combination and single therapy (25.6% [23 of 90] versus 27.8% [22 of 79]; adjusted HR, 0.87; 95% CI, 0.47 to 1.62; P = 0.660). These findings were consistent for 14-day all-cause mortality. In this large cohort, we found for the first time that combination therapy with beta-lactams and fluoroquinolones was associated with a reduction in 28-day all-cause mortality among less severely ill patients with bacteremia caused by gram-negative bacilli.
A Backpack and a Mission: The Journey of a Missionary Nurse
Eucken, Emily

Mayo Clinic

Creative Nursing | January 6, 2009 | Volume: 14 | Issue: 4 | Pages: 149-151

10.1891/1078-4535.14.4.149 | PMID 19090083 Get It

A medical mission to a small village in Fiji brought improved health care to a community and an indelible change in a nurse's heart.
Factors Associated with Breast Cancer Prevention Communication between Mothers and Daughters
Frost, Marlene H., Vierkant, Robert A. , Petersen, Larra R., Rock, Emily, Clark, Lara P. , Vachon, Celine M. , Fredericksen, Zachary S., Sellers, Thomas A. , Cerhan, James R. , Sinicrope, Pamela S. , Brockman, Tabetha A. , Patten, Christi A. , Vachon, Celine M. , Cerhan, James R , Vierkant, Robert A

Mayo Clinic

Journal of Women's Health | June 13, 2008 | Volume: 17 | Issue: 6 | Pages: 1017-1023

10.1089/jwh.2007.0497 | PMID 18554093 Get It

Objective: Mother-daughter communication may be a potential pathway between family history and cancer prevention behavior. We examined the degree to which mothers reported providing advice on breast cancer prevention to their daughters, the content of such advice, and correlates of providing such advice. Methods: Data were collected via a mailed questionnaire to 1773 women from 355 families in the Minnesota Breast Cancer Family Study. Women were asked whether or not they had provided advice to their daughters on what they should do to prevent breast cancer. An additional open-ended question asked them to describe the types of advice they had provided. Results: Nine hundred seventy-six (55%) of the women reported providing breast cancer prevention advice to their daughters. The most frequent types of advice were to have a mammogram (51%), perform breast self-examination (BSE) (39%), have a clinical breast examination (CBE) (30%), and maintain a healthy lifestyle (21%). From multivariate logistic regression, older age ( p < 0.001), having a personal history of breast cancer ( p < 0.001), higher degree of breast cancer worry/concern ( p < 0.001), engaging in a higher number of health-promoting behaviors ( p < 0.001), and ever performing a BSE ( p = 0.04) were factors independently associated with the provision of advice. Analyses accounting for sample nonindependence did not change our results. Conclusions: Breast cancer prevention behaviors were associated with providing advice. By better understanding the pathways through which breast cancer family history is associated with screening mammography and other prevention behaviors, researchers can develop more effective, tailored prevention interventions at the family level.